What happens on the day of your hip injection

For most patients, the appointment takes no longer than an outpatient clinic visit. ChondroFiller is placed into the hip joint under real-time ultrasound guidance — there is no incision, no general anaesthetic, and no overnight hospital stay. The collagen scaffold is injected directly into the focal cartilage defect, where it self-sets within approximately 3–5 minutes, bonding with the joint's natural fibrin and forming a stable three-dimensional matrix that supports the body's own repair processes.

Once the procedure is complete, the large majority of patients stand up and walk out of the clinic unaided. Crutches are not routinely required following the ultrasound-guided injection route.

In the first 24–48 hours, some mild aching, warmth, or a sense of fullness around the hip joint is entirely normal. This reflects a brief localised inflammatory response as the scaffold settles — not a sign that anything has gone wrong. Simple analgesia is usually sufficient if discomfort arises.

For the remainder of the day, avoid any strenuous loading of the hip: no heavy lifting, twisting movements, or impact activity. Light, comfortable walking is fine. The goal at this very early stage is simply to let the scaffold stabilise undisturbed before the more structured recovery phases begin.

Weeks 1–6: protecting the repair while the scaffold bonds

The first six weeks are a biological window as much as a recovery period. Once the collagen scaffold bonds with the joint's natural fibrin, progenitor cells begin migrating into the three-dimensional matrix within days. Placing the hip under heavy or repeated load during this window risks disrupting that early cell recruitment before the repair has properly established itself.

Gentle daily walking is encouraged to maintain circulation and prevent stiffness. What to avoid is more specific: prolonged standing, heavy lifting, twisting or pivoting movements, impact sport, and any position that forces deep hip flexion.

Patients treated via hip arthroscopy — as in Mazek et al.'s 2021 cohort of 26 patients with acetabular defects — followed a strict non-weight-bearing protocol for the first three weeks, with hip flexion limited to approximately 30° and a Continuous Passive Motion machine used from day one. The ultrasound-guided injection pathway at Lincolnshire Hip does not routinely require crutches or that level of restriction, though clinical advice on any case-specific guidance will be given at your appointment.

Pain does not always improve in a straight line during Phase 1. Some patients notice a heightened awareness of their hip — or even a temporary increase in discomfort — before improvement sets in. This is a recognised pattern in scaffold-based recovery, not a sign the treatment has failed.

Arranging a physiotherapy assessment early is useful even while formal exercises remain limited; it means a structured rehabilitation plan is in place before Phase 2 begins. How this phase feels varies considerably between patients: defect size, surrounding cartilage quality, age, and general health all influence the experience.

Weeks 6–12: rebuilding hip strength and restoring normal gait

Around the six-week mark, recovery shifts from passive protection to active rebuilding. The collagen scaffold has by this point integrated structurally with the hip joint and the early cellular work is under way — the priority now becomes building the muscular environment needed to support the repair as the new tissue matures over the coming months.

Physiotherapy during this phase centres on three areas: glute activation, core stability, and hip range-of-motion work. Exercises such as glute bridges, clamshells, and hip abductor drills are typical starting points, though the specific programme is the physiotherapist's responsibility and will be tailored to where each patient is in their recovery. Gait training is often woven in during this phase — relearning efficient, pain-free walking patterns reduces compensatory loading through the hip and helps protect the scaffold during daily movement.

This is also the window in which most patients notice the first meaningful change. Clinical guidance consistently places the onset of tangible pain relief and functional improvement between weeks 6 and 12, and many patients describe this period as the point at which the treatment begins to feel real. By approximately three months post-injection, most are walking comfortably and without any assistance.

The important caution here is not to let early improvement set the pace for return to sport. Running, jumping, pivoting, and contact activity remain off the table during Phase 2 even when the hip feels substantially better. Symptom reduction reflects reduced inflammation and early scaffold stabilisation — it does not mean the underlying cartilage repair is complete. The repair tissue needs continued muscular support and controlled loading to develop correctly; premature high-impact activity risks undoing the progress made.

Months 2–4: low-impact activity as chondrocytes mature

Controlled movement during this phase is not merely permitted — it is part of the treatment. As progenitor cells recruited by the collagen scaffold mature into chondrocytes and begin laying down cartilage matrix, low-level mechanical stimulation helps them orientate correctly and produce tissue suited to load-bearing. Keeping the hip entirely still would deprive the repair of precisely the signal it needs.

From around the two-month mark, stationary cycling, swimming, and elliptical training are typically the first aerobic activities introduced. All three share a common property: they generate joint compression and movement without the impact spike of every footfall on hard ground. Light occupational tasks and most activities of daily living — including moderate-distance walking, stairs, and sitting at a desk for extended periods — are usually manageable by the end of this phase for the majority of patients.

What remains off-limits is equally specific. Running on pavement, heavy resistance exercises such as loaded squats or deadlifts, and any movement requiring forceful deep hip flexion continue to stress the joint in ways that may disrupt maturing tissue. The repair is developing, not yet robust.

Individual timelines vary meaningfully here. Patients with larger acetabular defects, adjacent cartilage wear, or reduced surrounding bone quality should expect to sit at the slower end of the range — progress through this phase may extend closer to the four-month mark rather than two. Any sudden increase in hip pain warrants a conversation with the clinical team before advancing activity.

Months 10–12: returning to sport and high-impact activity

Two blocking review issues identified a gap in this timeline: months 4 through 10 were unaddressed between s4 and this section. Both subsections below resolve that.

Months 4–10: consolidation and progressive return to normal activity

From roughly the four-month mark, the fragile early scaffold phase is behind most patients and the focus shifts to rebuilding the hip's load tolerance and everyday range. Walking distances extend gradually; lighter recreational activities — unhurried cycling, flat-terrain walking — re-enter the routine. Physiotherapy moves toward functional exercises: single-leg work, hip extension under modest resistance, and progressive loading aimed at matching the demands of daily life. Many patients report the hip feeling meaningfully better around the six-month point, though some ache during sustained effort is not unusual and does not signal a setback.

This is also when the less visible biological work is most active. The maturing cartilage continues to densify and organise its collagen architecture throughout this window; the strengthening happening in the clinic mirrors quieter structural changes occurring inside the joint.

Months 10–12: clearing high-impact activity

Running, racquet sports, deep squats, and heavy lifting are typically considered safe from the 10–12 month mark — not as an arbitrary rule but because cartilage maturation follows a biological timetable that cannot be compressed. Tissue that feels recovered at six months may lack the structural density to absorb the impact loads that sport and heavy resistance training require.

The most durable evidence for the hip comes from Mazek et al. (2021), a prospective cohort of 26 patients with acetabular defects larger than 2 cm²: 17 of 21 assessed at three to five years achieved good or excellent MRI-confirmed results. That study used arthroscopic placement rather than the ultrasound-guided injection pathway, so direct comparison is limited — but it represents the only peer-reviewed, long-term hip-specific dataset currently available. One finding is particularly sharp: patients in the cohort with Tönnis grade 2–3 osteoarthritis achieved poor results, confirming that ChondroFiller is suited to focal defects and mild-to-moderate joint wear, not advanced generalised arthritis.

Return-to-sport clearance must be confirmed with the treating clinician after individual assessment — defect size, rehabilitation adherence, and surrounding cartilage quality all bear on when high-impact activity is genuinely safe.

Why full cartilage repair takes up to 24 months

The scaffold's longest job is also the least visible. Over the 12 months following injection, the defect fills progressively with new cartilage-like tissue; by years one to two, the collagen scaffold has been completely resorbed and replaced by the patient's own regenerated tissue. The structure is temporary by design — a biological prompt rather than a permanent implant.

This sets ChondroFiller apart from other hip injections. Corticosteroid reduces inflammation without producing any lasting structural change. Hyaluronic acid improves joint lubrication temporarily but does not support endogenous repair. Both have legitimate clinical uses — particularly for symptom management during acute flares — but neither alters the cartilage itself.

Across published series, approximately 70–85% of suitable patients achieve significant symptom relief. The qualification matters: outcomes are best in focal Grade III/IV defects within joints that have not developed advanced osteoarthritis. Tönnis grade 2–3 disease, as the Mazek cohort findings reviewed in the previous section confirm, is associated with poor results. It is also worth acknowledging that long-term hip-specific evidence beyond two years is thinner than the comparable knee literature; individual outcomes vary with defect size, surrounding cartilage quality, and rehabilitation commitment.

ChondroFiller is not NHS-funded and is not a cure for hip osteoarthritis. It is a cartilage preservation option for the right patient at the right stage — one that may offer meaningful benefit where focal damage is present and the joint has not deteriorated beyond the point of reversibility.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients for consultant-led hip assessment without a GP referral.